Emerging therapies for progressive multiple sclerosis (PMS) increasingly target CNS-compartmentalized inflammation driving progression independent of relapse activity. Six pivotal trials are evaluating Bruton's tyrosine kinase inhibitors, CD40-CD40L blockade, and CD19-directed CAR-T cells. Together, these studies may establish mechanism-based strategies to modulate microglia and B cell pathology, redefining treatment of progression and addressing a major unmet clinical need.
Progressive multiple sclerosis: Six trials to watch / Rocca, M.A., Preziosa, P., Filippi, M.. - In: MED. - ISSN 2666-6359. - 7:1(2026). [10.1016/j.medj.2025.100960]
Progressive multiple sclerosis: Six trials to watch
Rocca M. A.
Primo
;Preziosa P.Secondo
;Filippi M.Ultimo
2026-01-01
Abstract
Emerging therapies for progressive multiple sclerosis (PMS) increasingly target CNS-compartmentalized inflammation driving progression independent of relapse activity. Six pivotal trials are evaluating Bruton's tyrosine kinase inhibitors, CD40-CD40L blockade, and CD19-directed CAR-T cells. Together, these studies may establish mechanism-based strategies to modulate microglia and B cell pathology, redefining treatment of progression and addressing a major unmet clinical need.| File | Dimensione | Formato | |
|---|---|---|---|
|
MED 7_100960.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
2.5 MB
Formato
Adobe PDF
|
2.5 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
